Two UK deaths feared linked to weight-loss jabs, regulators say

Two deaths in the United Kingdom are being investigated for a possible link to widely used weight‑loss injections, regulators have said. The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that both a man and a woman were reported to its adverse event database, with investigators examining whether the fatalities may be linked to GLP‑1 receptor agonist medicines commonly prescribed for obesity and type 2 diabetes. No definitive conclusion has been reached, and officials stress that such signals require careful assessment against the medicines’ overall benefits.

Across the UK, regulators continue to monitor safety signals as more than 500 adverse drug reaction reports were logged in Northern Ireland between 2024 and 2025, reflecting ongoing scrutiny of new weight‑loss therapies.

Health authorities emphasise that adverse events are rare relative to the number of people treated, and the jabs have helped many people lose weight and improve metabolic health. Still, experts say that any potential risks may become clearer only with longer-term data and broader population analyses.

Regulators have urged clinicians and patients to report any unexpected or severe reactions and to discuss risk/benefit with healthcare providers. If a patient experiences severe abdominal pain, persistent vomiting, or signs of pancreatitis, seek medical attention.

Events like these underscore the importance of robust post‑marketing surveillance as weight‑loss therapies become more common. Regulators say they will publish updates as more data become available and will adjust safety guidance if needed.

#WeightLossJabs #MHRA #DrugSafety